Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Revenue projections:

Revenue projections for ABBV
Revenue projections for ABBV

ABBV's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 0.000000
forwardPE 12.652018
debtToEquity 0.000000
earningsGrowth -0.458000
revenueGrowth 0.124000
grossMargins 0.720260
operatingMargins 0.315560
trailingEps 2.040000
forwardEps 16.205320

AbbVie Inc.'s Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
ABBV's low earnings and revenue growth suggest that its profits could shrink. This points to a potential downturn in the company's financial outlook and may indicate challenges in maintaining profitability.
Positive gross and operating margins for ABBV highlight the company's profitability. These metrics reflect ABBV's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
AbbVie Inc.'s forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that AbbVie Inc. is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for ABBV
Price projections for ABBV

Over time, price projections for ABBV have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in ABBV's ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for ABBV
Insider Transactions for ABBV


AbbVie Inc. stock was sold in 8 transactions, with market price at 215.91625022888184.No sell transactions were completed during the period under review.The higher number of buys versus sells near ABBV's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for ABBV
Recommendations trend for ABBV


ABBV has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view ABBV as a reliable choice for their money, offering a promising avenue for future growth and financial gains.